Calidi Biotherapeutics effects 1-for-16 reverse stock split
CLDI•1-for-16 reverse stock split takes effect
Calidi Biotherapeutics executed a 1-for-16 reverse stock split of its common stock, effective July 30, 2026.
- Shares began trading on a split-adjusted basis July 31, 2026 on NYSE American under ticker CLDI.
- The move was aimed at lifting the share price to support continued NYSE American listing, reducing delisting risk tied to listing standards.
- Holdings were converted at 1-for-16, rounded up to whole shares; no fractional shares or cash payments were issued.
- Common stock received a new CUSIP: 320703 507.
